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a b s t r a c t
Hyperphosphorylation and ﬁbrillar aggregation of themicrotubule-associated protein tau are key features
of Alzheimer’s disease and other tauopathies. To investigate the involvement of tau phosphorylation in the
pathological process, we generated a pair of complementary phosphomutant tau knockinmouse lines. One
exclusively expresses phosphomimetic tau with 18 glutamate substitutions at serine and/or threonine
residues in the proline-rich and ﬁrst microtubule-binding domains to model hyperphosphorylation,
whereas its phosphodefective counterpart has matched alanine substitutions. Consistent with expected
effects of genuine phosphorylation, association of the phosphomimetic tau with microtubules and
neuronal membranes is severely disrupted in vivo, whereas the phosphodefective mutations have more
limited or no effect. Surprisingly, however, age-related mislocalization of tau is evident in both lines,
although redistribution appears more widespread and more pronounced in the phosphomimetic tau
knockin. Despite these changes, we found no biochemical or immunohistological evidence of pathological
tau aggregation in mice of either line up to at least 2 years of age. These ﬁndings raise important questions
about the role of tau phosphorylation in driving pathology in human tauopathies.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Neurodegenerative disorders termed tauopathies are charac-
terized by aggregation of microtubule-associated protein tau into
neuroﬁbrillary tangles (NFTs). Among these, Alzheimer’s disease
(AD) is the most common, but mutations in the MAPT gene
encoding tau have yet to be implicated as a causative factor. Instead,
MAPT mutations are associated with a familial tauopathy, fronto-
temporal dementia with parkinsonism linked to tau mutations on
chromosome 17 (FTDP-17T), which is an early-onset, autosomal-
dominant disorder (Wolfe, 2009). Although there is currently no
clear unifying mechanism to encompass the effects of all the
different FTDP-17T mutations, which include disruption of tau
microtubule binding and alterations in the proportion of tau
isoforms with 3 or 4 microtubule-binding domain (MTBD) repeats
(3R or 4R tau), ultimately they all promote the formation of
somatodendritic NFTs.
Tau is a phosphoprotein and over 40 serine, threonine, and
tyrosine residues have been identiﬁed as sites of physiological or
disease-associated phosphorylation (Hanger et al., 2009). Although
a variety of kinases have the potential to phosphorylate these sites,
the number of true in vivo tau kinases is probably more limited
(Hanger et al., 2009). Phosphorylation of tau is less extensive in
adult brain than fetal brain, but tau does become relatively hyper-
phosphorylated in NFTs and this occurs at many of the same sites
that are phosphorylated during early development (Brion et al.,
1993; Johnson and Stoothoff, 2004). However, because develop-
mental phosphorylation of tau does not promote ﬁlamentous ag-
gregation, the precise relationship of tau hyperphosphorylation to
the pathological process leading to tauopathy remains unclear.
Many mouse models have been created to investigate the role of
tau dysfunction in neurodegeneration, but the majority involve
transgenic expression of nonphysiological levels of wild-type
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human tau isoforms or human tau isoforms bearing FTDP-17T
mutations in the presence of endogenous murine tau (Denk and
Wade-Martins, 2009; Noble et al., 2010). Although tau phosphor-
ylation is often increased in these mice, assessing its impact sepa-
rately from the effects of disease mutations, increased expression,
and/or altered tau isoform ratios is not possible. Overexpression or
activation of known tau kinases, such as glycogen synthase kinase-
3b and cyclin-dependent kinase 5, increases tau phosphorylation
and can also enhance somatodendritic aggregation of endogenous
murine tau or transgene-expressedwild-type ormutant human tau
in mice (Ahlijanian et al., 2000; Cruz et al., 2003; Noble et al., 2003;
Spittaels et al., 2000; Terwel et al., 2008); however, these kinases
are relatively promiscuous meaning that any experimental
outcome cannot be conclusively attributed to speciﬁc tau phos-
phorylation sites, or even to their effects on tau alone.
More recently, transgenic mice expressing a permanently
pseudohyperphosphorylated phosphomimetic human tau mutant,
referred to as PHP tau, were generated to address the role of tau
hyperphosphorylation more directly (Hundelt et al., 2011). Sur-
prisingly, expression of PHP tau did not promote signiﬁcant tau
aggregation, NFT formation, or neurodegeneration in these mice,
but this could have been due to a relatively low level of PHP tau
expression and/or the unexpectedly limited effect that speciﬁc
subset of modiﬁed sites appeared to have on normal tau function.
Here, we have generated two novel, complementary knockin
mouse lines to investigate further the impact of phosphorylation of
tau at multiple sites on both its normal physiological function and
its potential role in driving pathological change. One exclusively
expresses a stably pseudohyperphosphorylated tau mutant in
which 18 phosphomimetic negative charges have been introduced
at speciﬁc sites via glutamate substitutions, whereas its counterpart
exclusively expresses phosphodefective tau in which incorporation
of alanines at the same sites prevents phosphorylation. Comparison
between the two should allow us to distinguish potentially
phosphorylation-dependent effects from unrelated structural ef-
fects of the mutations. Sixteen of the modiﬁcations are concen-
trated in the proline-rich domain (PRD), located centrally in tau in a
region containing an unusually high density of potential sites of
proline-directed phosphorylation, with the two othermodiﬁcations
located in the ﬁrst MTBD. Most of themodiﬁcations are known sites
of phosphorylation in AD brain tau (Hanger et al., 2009) and/or are
sites that have been shown to be phosphorylated in murine tau in
wild-type and human APP transgenic mice (Morris et al., 2015).
Although the average phosphate content of hyperphosphorylated
insoluble tau in AD brains shows interindividual variation of be-
tween 3 and 15 mol phosphate per mol of tau (Kopke et al., 1993;
Ksiezak-Reding et al., 1992), the range at the single molecule
level, likely within a highly heterogeneous pool of tau species, is
probably even greater. If the overall amount of tau phosphorylation
correlates with pathogenicity, then the phosphomimetic tau
mutant, with 18 pseudophosporylated sites, might be expected to
broadly replicate the effects of some of the most extensively
hyperphosphorylated AD-associated tau species. The mutants may
also provide additional insight into the role of phosphorylation of
residues within the speciﬁc domains targeted in this study, both of
which are key regulatory regions involved in protein interactions
(Ittner and Gotz, 2011; Kolarova et al., 2012; Mietelska-Porowska
et al., 2014). Crucially, our phosphomimetic mutant also has a
greater pseudophosphorylation load than PHP tau (10 sub-
stitutions), and the complement of modiﬁcations is largely
nonoverlapping (Hundelt et al., 2011).
We ﬁnd that some key properties of tau are altered in a largely
phosphorylation-dependent manner in these mice, including
reduced interactions with microtubules and membranes. These are
consistent with established in vitro effects of phosphorylation at a
variety of sites in tau, including some of those mutated here,
although this particular combination of sites has not previously
been studied in any context. We also see signiﬁcant mislocalization
of both tau mutants, with strong reductions in axonal tau and in-
creases in somatodendritic tau in some neuron types in both lines.
Structural changes in the PRD, rather than pseudophosphorylation,
may thus be key, although there is also some evidence for earlier
andmore pronounced changes in the phosphomimetic tau knockin.
Notably, despite these observed changes in tau properties, we could
not detect pathological aggregation of tau in either line. We discuss
the implications of these results with respect to the role of exten-
sive tau phosphorylation on normal tau function and in neurode-
generative diseases.
2. Materials and methods
2.1. Generation of knockin mice expressing phosphomimetic and
phosphodefective tau
Serine and threonine codons in human MAPT exon 9 (within a
plasmid containing the whole MAPT coding region) were mutated
to glutamate or alanine by QuikChangeII site-directed mutagenesis
(Stratagene, La Jolla, CA, USA). Polymerase chain reaction (PCR)
cloning was used to generate the targeting vectors (Fig. 1A) for each
knockin (identical bar the mutations) using pEasy-Flox as a back-
bone (a gift from Profs. W. Müller and K. Rajewsky). Brieﬂy, the 50
arm (50 to the Neor cassette) was generated by ligation of the
mutant human MAPT exon 9 (either with 9E18 or 9A18 mutation
sets) to sequences ﬂanking the mouse MAPT exon 9, using restric-
tion sites and ﬂanking sequences introduced into the PCR primers
so that ﬂanking intronic regions remained unaltered. The 30 arm
was cloned as a single fragment. The ﬂanking mouse genomic re-
gions were ampliﬁed by PCR from C57BL/6J mouse bacterial artiﬁ-
cial chromosomes (Children’s Hospital, Oakland Research Institute).
Linearized targeting vector was electroporated into C57BL/6-
Thy1.1-derived Bruce 4 embryonic stem (ES) cells by the Babra-
ham Institute Gene Targeting Facility. Correctly targeted G418-
resistant clones for each knockin were identiﬁed by Southern blot
analysis of SpeI-digested genomic DNA using ﬂanking 50 and 30
probes (positions shown in Fig. 1A) and were injected into C57BL/
6J-Tyrc-2J (albino) blastocysts and transferred to pseudopregnant
women (C57BL/6JOlaHsd  CBA/Ca). Resulting chimeric male
offspring were mated to C57BL/6J-Tyrc-2J women and germ line
transmission of the mutant allele assessed by Southern blotting. Cre
recombinase-mediated excision of the ﬂoxed neomycin-resistance
cassette (Neor) was performed by mating to C57BL/6J deleter
mice bearing a ubiquitously expressed X-linked Cre transgene
(kindly provided by Miguel Constancia). Mice were PCR genotyped
for presence of the knockin alleles using primers 50-
TTGGGGTCACCCTACTGACTTC-30 and 50-GACTGAGGAATGGTTCA-
CAGCC-30 (primer locations and representative results are shown in
Fig. 1A and B). Normal Mendelian ratios were obtained from het-
erozygote crosses. Mice were bred to homozygosity so that mice
expressing only each tau mutant were studied. All mice were bred,
housed, and used in accordance with the UK Home Ofﬁce Animals
(Scientiﬁc Procedures) Act, 1986, under Project Licenses PPL 80/
1778, 80/2254, and 70/7620.
2.2. Cell culture and transfection
Superior cervical ganglia (SCGs) obtained from P1 or P2 mouse
pups were plated whole onto 3.5-cm tissue culture dishes pre-
coated with poly-L-lysine (20 mg/mL for 1e2 hours; Sigma) and
laminin (20 mg/mL for 1e2 hours; Sigma) for SCG explant cultures.
For dissociated SCG cultures, ganglia were incubated in 0.025%
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trypsin (Sigma) in PBS (without CaCl2 and MgCl2) for 30 minutes
followed by 0.2% collagenase type II (Gibco) in PBS for 30 minutes
before gentle trituration using a 1-mL plastic pipette tip. After a
2-hour preplating step (to remove non-neuronal cells), neurons
were plated on poly-L-lysine and laminin-coated ibidi m-dishes
(Thistle Scientiﬁc). Explant and dissociated SCG cultures were
maintained in Dulbecco’s Modiﬁed Eagle’s Mediumwith 4500mg/L
glucose and 110mg/L sodium pyruvate (Sigma), supplementedwith
10% fetal bovine serum (Sigma), 100 ng/mL 7S NGF, 1% penicillin
and/or streptomycin, and 2-mM L-glutamine (all Invitrogen). Pro-
liferation and viability of small numbers of non-neuronal cells were
inhibited by 4-mM aphidicolin (Calbiochem). Separate ganglia and
neurite fractions for immunoblotting were generated from explant
cultures essentially as described previously (Gilley and Coleman,
2010). Brieﬂy, ganglia were separated from their neurites with a
scalpel. Neurites and ganglia were then collected separately,
washed in PBS, lysed in 2 Laemmli buffer, and heated at 100 C
(10 minutes) before analysis.
For dissociated cortical neuron cultures, cortical tissue (with
meninges removed) was dissected from P1 or P2 mouse pups and
incubated in 0.025% trypsin for 20 minutes followed by gentle
trituration using a 1-mL plastic pipette tip. The course cell sus-
pension was then passed through a 70-mm strainer (Corning).
Neurons were plated on 3.5-cm tissue culture dishes precoated
with poly-L-lysine and laminin (as for SCGs) and maintained in
Neurobasal Medium (Invitrogen) supplemented with 2% B27 sup-
plement (Invitrogen), 1% penicillin and/or streptomycin, and 2-mM
L-glutamine.
Chinese hamster ovary (CHO) cells were cultured in Ham’s F12
medium (Invitrogen) supplemented with 10% fetal bovine serum,
1% penicillin and/or streptomycin, and 2-mM L-glutamine. CHO
cells were transfected using Lipofectamine (Invitrogen) following
the supplied instructions.
2.3. Reverse transcriptase PCR (RT-PCR)
RNA extraction and RT-PCR were performed essentially as
described previously (Gilley et al., 2012). A region spanning murine
MAPT exons 7 to 11 were ampliﬁed using primers 50-
CGTCCAACGCCACCAGGATCC-30 and 50-CTGGCTTGTGATG-
GATGTTCC-30 for sequencing to conﬁrm that only mutant mRNA is
expressed in the homozygous knockin mice. A region spanning
murine MAPT exons 10 to 13 were ampliﬁed using primers 50-
GAAGCTGGATCTTAGCAACGTCC-30 and 50-TTATTGACTGCCCTGG-
GAGCC-30 for semiquantitative end point RT-PCR analysis of MAPT
levels in the mutant mice. This was performed as described previ-
ously (Gilley et al., 2013). b-actin (Actb) transcripts, acting as the
sample reference, were ampliﬁed using primers 50- TGTTAC-
CAACTGGGACGACA-30 and 50-ATGAGGTAGTCTGTCAGGTC-30. MAPT
exon numbering is based on accepted human MAPT gene structure
(Andreadis et al., 1992).
2.4. Fractionation and dephosphorylation of brain lysates for
immunoblot analysis
For crude extracts, whole brains from adult mice were
mechanically homogenized using an Ultra-Turrax homogenizer in
1 TG lysis buffer consisting of 20-mM Tris (pH 7.5), 137-mM NaCl,
1-mM EGTA, 1% (v/v) Triton X-100, 10% (v/v) glycerol, 1.5-mM
MgCl2, 1-mM Na3VO4, 50-mM NaF, and cOmplete Mini protease
inhibitor cocktail (Roche). Samples were centrifuged at 10,000 g for
5 minutes at 4 C to pellet cell debris. The supernatant was diluted
in 2 Laemmli sample buffer for immunoblot analysis.
Fractionation of brain lysates was performed essentially as
described previously (Gilley et al., 2012) but with minor
modiﬁcations. Dissected mouse cortices (one hemisphere) snap-
frozen in liquid nitrogen were later homogenized on ice in 600-
mL MES buffer (100-mM 2-(N-morpholino)ethanesulfonic acid
(MES) pH 6.5, 0.5-mM MgCl2, 1-mM EGTA, 1-M NaCl, 25-mM b-
glycerophosphate, 50-mM imidazole, 20-mM NaF, 10-mM Na4P2O7,
and protease inhibitor cocktail (Sigma)) using an Ultra-Turrax
homogenizer (20 seconds). Cellular debris was removed by
centrifugation at 27,000 g(av) for 30 minutes at 4 C and 350 mL of
supernatant was then centrifuged at 100,000 g(av) for 1 hour at 4
C. The entire pellet, containing insoluble tau, was then resus-
pended directly in 400 mL 2 Laemmli SDS-PAGE sample buffer
and an aliquot of the 100,000 g supernatant, containing soluble
tau, was diluted 10 into 2 Laemmli buffer. Fractions were
assessed by immunoblotting.
For dephosphorylation assays, soluble fractions generated as
mentioned previously (before the addition of Laemmli buffer) were
dialyzed to 50-mM Tris pH 7.5 for 1 hour and then incubated with
or without l protein phosphatase (NEB Biolabs) for 2 hours at 30 C.
Reactions were stopped by boiling for 5 minutes. Equal amounts of
phosphatase-treated and untreated lysates diluted in 2 Laemmli
buffer were heated at 100 C (10 minutes) and assessed by
immunoblotting.
2.5. Endogenous microtubule-binding assay
We used a modiﬁcation of an in situ microtubule-binding assay
(Ding et al., 2006), essentially as described previously (Gilley et al.,
2012; Rodriguez-Martin et al., 2013). Freshly dissected half brains
(no cerebellum), or PBS-rinsed CHO cells transfected for 24 hours
with plasmids (pEGFP-C1 backbone) expressing eGFP-tagged wild-
type human tau (eGFP-htau), human 9E18tau (eGFP-h9E18tau), or
human 9A18tau (eGFP-h9A18tau), were homogenized in warm
microtubule stabilizing buffer (80-mM PIPES/KOH, pH 6.8, 1-mM
GTP, 1-mM MgCl2, 1-mM EGTA, 0.5% Triton X-100, 30% glycerol,
0.5-mM okadaic acid and 10-mM Taxol and 1 protease inhibitor
cocktail). Homogenized samples were centrifuged at 5000 g(av) for
10minutes at room temperature (RT). An aliquot of the supernatant
was retained as the postnuclear lysate “input” fraction. The
remaining postnuclear lysate was then centrifuged at 100,000 g(av)
for 1 hour at 25 C with the resulting supernatant representing the
“soluble” fraction and the pellet the “microtubule” fraction The
pellet was rinsed twice in PBS before being resuspended in the
same volume of microtubule-stabilizing buffer as the amount of
supernatant recovered. Fractions were diluted in 2 volumes of 2
Laemmli buffer, heated at 100 C for 10 minutes, and equal volumes
assessed by immunoblotting. Prewarming microtubule-stabilizing
buffer to 37 C (rather than RT) before addition to the half brains
in this study may account for the slightly higher microtubule
fraction yields obtained compared to those seen previously (Gilley
et al., 2012).
2.6. Cell fractionation for membrane association assays
Mouse cortical tissue was disrupted in hypotonic buffer (10-mM
sodium bicarbonate containing 20-mg/mL deoxyribonuclease I
(DNase I), 1-mM sodium orthovanadate, and Complete protease
inhibitor cocktail) by sonication using 5 strokes with probe soni-
cator on ice. Samples were then processed as described previously
(Pooler et al., 2012). Brieﬂy, lysates were centrifuged at 720 g for
5 minutes at 4 C. The supernatant was then removed and centri-
fuged at 100,000 g for 1 hour at 4 C. The ﬁnal supernatant (cyto-
solic fraction) and the pellet (membrane fraction) were
resuspended in Laemmli sample buffer and heated at 100 C
(10 minutes) before immunoblot analysis.
J. Gilley et al. / Neurobiology of Aging 39 (2016) 1e18 3
Fig. 1. Generation of Mapt-9E18 and Mapt-9A18 phosphomimetic and phosphodefective tau knockin mice. (A) Targeting strategy used to replace murine Mapt exon 9 (E9) with
human MAPT exon 9 (hE9) bearing 18 phosphomimetic or phosphodefective mutations to generate murine Mapt-9E18 or Mapt-9A18 knockin alleles. The targeting vector and
corresponding region of the murine Mapt locus are shown at key stages of the process (not to scale). The neomycin resistance cassette (Neor) was removed by in vivo Cre-mediated
recombination via ﬂanking loxP sites (large arrowheads). ES cell clones and founder mice were screened by Southern blotting of SpeI-digested genomic DNA using 50 and 30 probes
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2.7. Immunoblotting
Boiled samples were resolved in 10% or 12% (w/v) poly-
acrylamide gels before transfer onto Immobilon-FL PVDF mem-
brane (Millipore). Membranes were blocked with 5% (w/v) nonfat
dried milk (1 hour, RT) and then probed with the following primary
antibodies overnight at 4 C: DAKO antitau (1:5000e10,000);
TP007 anti-tau (1:1000) (Davis et al., 1995); AT270 (Innogenetics,
1:1000) recognizing phospho-T181 tau; PHF-1 recognizing
phospho-S396/S404 tau (gift from P. Davies, 1:2000); antibodies
recognizing tau phosphorylated at S356, S396, S404, S409, and
S422 tau (Invitrogen, 1:1000e2000); antisynaptophysin (DAKO or
Abcam Ab8049, 1:1000); TUJ1 monoclonal antineuronal class III b-
tubulin (Covance, 1:10,000e15,000); and AC15 anti-b-actin
(Abcam, 1:5000) (for all tau antibodies numbering is as in human
2N4R tau). Blots were washed and probed with AlexaFluor 680-
conjugated antimouse (Molecular Probes, Eugene, OR, USA) or
IRDye800-conjugated antirabbit (LI-COR Biosciences, Lincoln, NC,
USA) donkey secondary antibodies (both 1:5000) for 1e2 hours at
RT. Immunoblots were visualized and quantiﬁed using the Odyssey
imaging system (LI-COR Biosciences). The use of different per-
centage gels and/or varying run lengths likely accounts for the
differential resolution of tau species (particularly for 9E18tau)
which is apparent between different experiments. Quantities of
extract required to ensure immunodetection in the dynamic linear
range were determined empirically. Standard curves for antibodies
used in key quantitative analyses are shown in Supplementary
Fig. 7.
2.8. Gallyas silver-stain and immunohistochemical and/or
immunoﬂuorescent staining
Mouse brains and spinal cords were ﬁxed in 10% formalin for at
least 24 hours before dehydration and embedding in parafﬁn.
Gallyas silver staining of tissue sections (7-mm thick) for identiﬁ-
cation of NFTs was performed as described previously (Leroy et al.,
2007).
Immunohistochemical labeling of tissue sections was performed
using the ABC method. Sections were treated with 0.3% H2O2 to
inhibit endogenous peroxidase, blocked in 10% (v/v) normal horse
serum in TBS (0.01-M Tris, 0.15-M NaCl, pH 7.4), and incubated
overnight with diluted mouse monoclonal phosphorylation-
independent antimurine tau mTau2 (a generous gift from M.
Mercken, Johnson & Johnson, Beerse, Belgium) or B19 antibodies
(Brion et al., 1991), or AT270 or PHF-1 phosphorylation-dependent
antibodies (described previously). Sections were then incubated
with biotin-conjugated goat antirabbit or horse antimouse anti-
bodies followed by ABC complex (Vector Laboratories). Peroxidase
activity was developed using diaminobenzidine as the chromogen.
The optical density of tau staining in different layers of the cere-
bellumwas calculated from images (40 objective) using the public
domain ImageJ software (rsb.info.NIH.gov/nih-image/).
For immunoﬂuorescent labeling of tissue sections, rehydrated
sections were blocked in 10% (v/v) normal horse serum in TBS and
incubated overnight with monoclonal mTau2 and rabbit polyclonal
anti-neuroﬁlament-light (NF-L) antibody (NA1214, Enzo life sci-
ence, Belgium). Sections were then incubated with biotin-
conjugated horse antimouse and Alexa594-conjugated antimouse
secondary antibodies followed by ABC complex. Biotin-labeled
signal was ampliﬁed by Tyramid signal ampliﬁcation Fluorescein
system (Perkin Elmer). Sections were counterstained by DAPI (4’,6-
diamidino-2-phenylindole) before mounting in gelvatol.
For immunoﬂuorescent staining of dissociated SCG and cortical
neurons, cells were ﬁxed in 4% paraformaldehyde for 20 minutes,
permeabilized in 1% Triton X-100 in PBS for 10 minutes, and
blocked in 50% goat serum in PBS containing 1% BSA for 30minutes,
before being coincubated with DAKO antitau and TUJ1 antineuronal
class III b-tubulin antibodies (both 1:1000 in PBS,1% BSA for 1 hour)
followed by Alexa488-conjugated antirabbit and Alexa568-
conjugated antimouse secondary antibodies (1:200 in PBS, 1% BSA
for 1 hour). Cells were mounted in Vectashield containing DAPI
(Vector Laboratories) for counterstaining of nuclei.
For immunoﬂuorescent staining of transfected CHO cells, cells
were ﬁxed in 4% paraformaldehyde 24 hours after transfection,
blocked in 1% Triton X-100, 10% fetal bovine serum in PBS for
20 minutes, and then incubated with mouse monoclonal DM1A
anti-a-tubulin (Invitrogen) for 1 hour followed by an antimouse
Texas Red-coupled secondary antibody for 1 hour.
Images of stained sections were acquired using a Zeiss Axioplan
microscope and an Axiocam HRc camera. Bright ﬁeld and ﬂuores-
cence images of SCG or cortical cultures were captured on an
Olympus IX81 inverted ﬂuorescence microscope using a Soft Im-
aging Systems F-View camera linked to a PC running Soft Imaging
System software. Fluorescence microscopy of transfected COS cells
was performed using an Axioskop microscope (Zeiss), equipped
with a CoolSnap HQ camera (Photometrics). Images were processed
using Adobe Photoshop Elements 4.0 for presentation.
2.9. Measurements of cross-sectional areas of hippocampal regions
The public domain ImageJ software (rsb.info.NIH.gov/nih-
image/) was used to calculate the cross-sectional area of different
regions of the hippocampus after manual delineation of their
borders on low magniﬁcation images (5 objective) of
diaminobenzidine-stained sections at Bregma lateral 1.1e1.3 mm
probed with the B19 total tau antibody.
2.10. Analysis of mitochondrial transport
Mitochondrial transport in ex vivo tibial nerve axons of 5- to 9-
month-old wild-type,Mapt-9E18, orMapt-9A18mice heterozygous
for the Thy1-mitoCFP-S (Mito-S) transgene (Misgeld et al., 2007)
was assessed essentially as described previously (Andrews et al.,
2010; Gilley et al., 2012).
2.11. Statistical analysis
Appropriate statistical tests, as described in the text or ﬁgure
legends, were performed using Prism software (GraphPad Software
bordering the targeted region (restriction fragment sizes are shown). PCR primers (small arrowheads) ﬂanking the single retained loxP site after Neor deletion were used for
subsequent PCR genotyping of mice (see the following). (B) Illustration showing the 18 serine and threonine residues (white text on black background) that we mutated to glutamate
or alanine. All are potential phosphorylation sites that are conserved between human and mouse. Other common phosphorylation sites and key domains in human tau are also
labeled. Numbering relates to human 2N4R tau (441 amino acids). The equivalent residues in murine tau are S184, S187, S188, S191, T194, S197, S199, T201, S203, T206, T209, T220,
S224, S226, S230, T234, S247, and S251. (C) Typical PCR genotyping results for wild-type and homozygous knockin mice (left) compared to a heterozygous mouse (rightdnot
assessed in this study). (D) Representative immunoblots (of n ¼ 3) of total tau and bIII-tubulin, acting as a sample reference, in soluble fractions of brain lysates fromwild-type (wt),
Mapt-9E18 or Mapt-9A18 mice (aged 8 months), before or after treatment with l phosphatase. Positions of the predominant adult murine tau isoforms (0N4R, 1N4R, and
2N4Rdarrowheads) and a known N-terminally-cleaved species [(Takuma et al., 2003)dasterisk] are indicated. Abbreviation: ES, embryonic stem; PCR, polymerase chain reaction.
=
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Fig. 2. Effects of 9E18 and 9A18tau mutations on tau-microtubule relationships. (A) Representative immunoblots showing total tau (DAKO antibody) and bIII-tubulin (bIII-tub.)
levels in whole postnuclear brain extracts (Input) and derived soluble (SOL) and microtubule (MT) fractions fromwild-type, Mapt-9E18, and Mapt-9A18 mice (aged 11e12 months).
Graphs show the proportion of tau and bIII-tubulin in the microtubule fraction (as a percentage of soluble and microtubule fractions combined) and the ratio of tau to bIII-tubulin
(tau/tub.) in the microtubule fraction based on data from n ¼ 12 wild-types (wts) (pooled from each knockin line which were not signiﬁcantly different) and n ¼ 7 for each knockin.
Means  SEM are plotted with conversion of the tau/bIII-tubulin ratio data relative to a wild-type mean set at 1. *p < 0.05, **p < 0.01, ***p< 0.001, Kruskal-Wallis tests with Dunn’s
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Inc, La Jolla, CA, USA). A p value of >0.05 was considered not sig-
niﬁcant (ns) and *p < 0.05, **p < 0.01, and ***p < 0.001.
3. Results
3.1. Generation of knockin mice expressing phosphomimetic and
phosphodefective tau
We generated complementary phosphomimetic and phospho-
defective tau knockin mice using a homologous recombination
strategy targeting the endogenous murine MAPT gene. In short,
exon 9 of the mouse MAPT gene, encoding the PRD and ﬁrst MTBD,
was replaced with a mutated human MAPT exon 9 (84/88 amino
acid identity with mouse exon 9) in which 18 conserved serine and
threonine codons were changed to specify glutamate to mimic
phosphorylation, or alanine to prevent phosphorylation (Fig. 1A
and B). The two sets of tau mutations are hereafter referred to as
9E18 and 9A18, respectively. By incorporating the mutations
directly into the endogenous MAPT gene, we anticipated that in
mice homozygous for the modiﬁed alleles, the modiﬁed proteins
would be expressed at close to physiological levels, only in appro-
priate cell types, with a normal pattern of alternative splicing, and
in the absence of any wild-type murine tau. This should exclude the
potentially confounding inﬂuences of tau overexpression and/or
changes to tau isoform ratios that are often a feature of cDNA
knockin and transgene strategies (Gilley et al., 2011). Crucially, this
further differentiates these mice from PHP tau transgenic mice
(Hundelt et al., 2011).
Southern blotting conﬁrmed correct targeting of the Mapt-9E18
andMapt-9A18 knockin alleles, and mice were PCR genotyped after
Cre-mediated deletion of the neomycin resistance cassette in vivo
(Fig. 1A and C). Only mice homozygous for either theMapt-9E18 or
multiple comparisons post hoc analysis. Mice were 12 months old  1 month. (B) Representative immunoblots showing levels of exogenous eGFP-htau, eGFP-h9E18tau, or eGFP-
h9A18tau (GFP antibody) in whole postnuclear extracts (Input) and derived MT fractions from transfected CHO cells. The graph shows the proportion of tau in the microtubule
fractions relative to input. Means  SEM are plotted (n ¼ 3). Statistical signiﬁcance was tested using Kruskal-Wallis test with Dunn’s multiple comparisons post hoc analysis. (C)
Representative confocal images of CHO cells 24 hours after transfection with eGFP-htau, eGFP-h9E18tau, or eGFP-h9A18tau constructs showing eGFP ﬂuorescence and the dis-
tribution of a-tubulin (a-tub.). Microtubule bundling is seen as thick circular rings of a-tubulin. The graph shows the percentage of transfected CHO cells displaying clear bundling.
Means  SEM are plotted (n  9 independent transfections). ***p < 0.001, one-way analysis of variance with Tukey’s multiple comparisons post hoc analysis. Abbreviation: SEM,
standard error of the mean.
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Fig. 3. Reduced membrane association of 9E18tau, but not 9A18tau in brains. Immunoblots showing total tau and b-actin levels in total lysates and cytosolic and membrane fractions
derived the cortices of matched pairs (n ¼ 6) of (A) wild-type and Mapt-9E18 knockin mice, and (B) wild-type and Mapt-9A18 knockin mice aged 3.5e9 months. Graphs show the
ratio of tau in the membrane fraction compared to that in the cytosol fraction for the knockins as a proportion of that of their matched wild-type controls. Means  SEM are plotted
after conversion of the data sets relative to a wild-type mean set at 1. **p < 0.01, Mann-Whitney test. Abbreviation: SEM, standard error of the mean.
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Fig. 4. Phosphorylation status of 9E18tau and 9A18tau in soluble fractions of brain extracts fromMapt-9E18 andMapt-9A18 mice aged 8 or 24 months. Representative immunoblots
and quantiﬁcation of relative levels of total tau (DAKO antibody) and tau phosphorylated at murine residues equivalent to human S396 (pS396 antibody) and T181 (AT270 antibody)
in soluble fractions of brain extracts frommatched wild-type (wt) andMapt-9E18 mice (A), and wild-type (wt) andMapt-9A18 mice (B) aged 8 months or 24e26 (24þ) months. bIII-
tubulin (b-tub) acted as a loading reference. Graphs show levels of total tau (normalized to bIII-tubulin) and the relative level of phosphorylation at different phosphoepitopes
(normalized to total tau) in knockin brains as a ratio of that in wild-type brains. The ratio of each knockin sample relative to its paired wild-type control (individually set at 1) was
calculated to eliminate session-to-session technical variability. Means  SEM are plotted. Data were quantiﬁed from n ¼ 4 matched pairs at 8 months and n ¼ 5 matched pairs at
24e26 months. **p < 0.01, paired t tests (ratios of paired values). Migration of a 50-kDa size marker is shown to the right of the blots. Only the low molecular weight (LMW) tau
species (45e65 kDa) were included in this analysis. High molecular weight (HMW) tau bands (>90 kDa) were detected, but they represent only a minor proportion of the total tau
and intergenotype differences matched those seen for LMW tau. An HMW nonspeciﬁc band (<) is evident on the AT270 blots. Abbreviation: SEM, standard error of the mean.
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Fig. 5. No accumulation of insoluble 9E18tau or 9A18tau in brains of knockin mice at 8 or 24 months. Representative immunoblots and quantiﬁcation of relative levels of total tau in
insoluble fractions of brain extracts from matched wild-type and Mapt-9E18 mice (A), and wild-type and Mapt-9A18 mice (B) aged 8 months or 24e26 months. bIII-tubulin (b-tub)
acted as a loading reference. Graphs show levels of total tau (normalized to bIII-tubulin) and the ratio of insoluble to soluble tau (Insol/Sol) in knockin brains as a ratio of that in wild-
type brains. The Insol/Sol tau ratio was calculated by matching insoluble fractions to their soluble counterparts (Fig. 4). Insoluble tau actually represents less than 5% of total brain
tau (not shown). The ratio of each knockin sample relative to its paired wild-type control (individually set at 1) was calculated to eliminate session-to-session technical variability.
Means  SEM are plotted. Data were quantiﬁed from n ¼ 4 matched pairs at 8 months and n ¼ 5 matched pairs at 24e26 months for each line. Means  SEM are plotted. *p < 0.05,
**p < 0.01, paired t tests (ratios of paired values). The position of a 50-kDa size marker is shown to the right. Only LMW tau species (45e65 kDa) were detected. Abbreviations: LMW,
low molecular weight; SEM, standard error of the mean.
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Fig. 6. Age-related changes in subcellular distribution of 9E18tau and 9A18tau in the hippocampus of knockin mice. Immunohistochemical staining for total tau and neuroﬁlament-L
(NF-L) on brain tissue sections encompassing the hippocampus of wild-type,Mapt-9E18, andMapt-9A18 mice at 24 months (A) and at 3 weeks (B) reveals qualitative changes in the
relative distribution of the mutant tau proteins (N.B. this is separate from global differences in absolute staining intensity which likely reﬂect session-to-session variation in the
J. Gilley et al. / Neurobiology of Aging 39 (2016) 1e1810
Mapt-9A18 knockin alleles, hereafter referred to as Mapt-9E18 and
Mapt-9A18 mice, were examined in this study. Sequencing of Mapt
RT-PCR products conﬁrmed that only the relevant mutant Mapt
mRNA is detectable in the brains of the Mapt-9E18 and Mapt-9A18
mice, meaning that only phosphomimetic 9E18tau or phosphode-
fective 9A18tau is expressed.
Adult mice express primarily 4R tau isoforms and immuno-
blotting of phosphatase-treated brain lysates revealed that the ratio
of the 0N4R, 1N4R, and 2N4R tau isoforms inMapt-9E18 andMapt-
9A18 mice is broadly similar to that in wild-type mice (Fig. 1D).
Thus, splicing is largely unaffected by either set of mutations.
However, retarded electrophoretic mobility appears to be an
inherent property of 9E18tau, rather than the result of increased
phosphorylation at nonmutated sites, as it remains evident in
phosphatase-treated samples (Fig. 1D). Unexpectedly, steady-state
levels of 9E18tau in the brain are signiﬁcantly lower than those of
nonmutant tau in wild-type brains (49.5  7.7% of wild-type levels
after normalization to bIII-tubulin, p ¼ 0.043 paired t tests [ratios of
paired values], n¼ 3). In contrast, migration of 9A18tau is similar to
nonmutant tau inwild-typemice (Fig.1D), and its steady-state level
is not signiﬁcantly altered (105.6  7.9% of wild-type levels, p ¼
0.570, n ¼ 3). Similar relative expression patterns for the mutant
proteins were consistently detected in different brain extract
preparations and fractions, irrespective of the age of the animals,
the method of preparation, or the total tau antibody used (see
below). Intriguingly, RT-PCR analysis revealed an opposite trend for
the mutantMaptmRNAs (Supplementary Fig. 1);Mapt-9E18 mRNA
levels in Mapt-9E18 brains are modestly higher than nonmutant
MaptmRNA levels inwild-type brains (118.9 3.5% of control levels
after normalization to ActbmRNA, p ¼ 0.011 paired t tests [ratios of
paired values], n ¼ 4), whereas Mapt-9A18 mRNA levels in Mapt-
9A18 brains are almost halved (53.5  4.9%, p ¼ 0.006, n ¼ 4).
3.2. Differential effects of 9E18 and 9A18 mutations on tau-
microtubule relationships
The ability of tau to bind to and stabilize microtubules is inﬂu-
enced by phosphorylation (Bramblett et al., 1992, 1993; Busciglio
et al., 1995; Wagner et al., 1996) and by synthetic mutations that
either mimic or prevent phosphorylation (Rodriguez-Martin et al.,
2013). Therefore, we evaluated endogenous association of
9E18tau or 9A18tau with microtubules in the brains of Mapt-9E18
and Mapt-9A18 mice (Fig. 2A). The amount of 9E18tau in microtu-
bule fractions from Mapt-9E18 brains is reduced relative to that of
wild-type tau in control brains, consistent with extensive pseudo-
phosphorylation of tau severely disrupting its ability to bind to
microtubules. Intriguingly, however, the relative paucity of
microtubule-associated phosphomimetic tau has no effect on the
overall size of the microtubule fraction as levels of neuron-speciﬁc
bIII-tubulin in the Mapt-9E18 samples are similar to those from
controls. As a result, there is a large reduction in the ratio of tau to
bIII-tubulin in the Mapt-9E18 microtubule fractions. Conversely, a
statistically signiﬁcant reduction in the size of the microtubule
fractions fromMapt-9A18mouse brains, based on bIII-tubulin yield,
suggests that 9A18tau is defective for microtubule binding and/or
microtubule stabilization in someway, although there is potentially
a much more modest reduction in the amount of the mutant that is
actually associated with microtubules (not statistically signiﬁcant
due to sizable variation within the set) and a largely unaltered ratio
of tau to bIII-tubulin. These data suggest that both mutants are
dysfunctional for microtubule binding and/or microtubule stabili-
zation to some extent, but that the relationship is different for each
and is complex.
Any potential reduction in the amount of 9A18tau in the
microtubule fractions from Mapt-9A18 brains was somewhat un-
expected, given we previously found a related, but distinct, human
phosphodefective tau mutant, A18tau, to be increased in trans-
fected CHO cell microtubule fractions (Rodriguez-Martin et al.,
2013). We therefore compared recovery of microtubule-associated
eGFP-tagged human wild-type tau (eGFP-htau), human 9E18tau
(eGFP-h9E18tau), and human 9A18tau (eGFP-h9A18tau) from
transfected CHO cells (Fig. 2B). Importantly, the relative amounts of
eGFP-h9E18tau and eGFP-h9A18tau in the CHO microtubule frac-
tions broadly matched those of 9E18tau and 9A18tau in mouse
brains (compare Fig. 2A and B). Furthermore, consistent with the
known correlation between reduced microtubule-binding capacity
and a reduced ability of tau to induce microtubule bundling (Kanai
et al., 1989; Rodriguez-Martin et al., 2013; Wagner et al., 1996), we
found that eGFP-h9E18tau is unable to efﬁciently induce microtu-
bule bundling in CHO cells, whereas similar overexpression of
eGFP-h9A18tau promotes bundling that is comparable to wild-type
tau (Fig. 2C).
3.3. Reduced membrane association of 9E18tau but not 9A18tau
A proportion of endogenous tau has previously been shown to
associatewithmembranes in a variety of cell lines and in rat cortical
neurons, and this can be inhibited by phosphorylation (Arrasate
et al., 2000; Brandt et al., 1995; Maas et al., 2000; Pooler et al.,
2012). We therefore compared tau levels in membrane and
cytosol fractions of cortical extracts from adult wild-type, Mapt-
9E18, and Mapt-9A18 mice by immunoblotting (Fig. 3). We found
that the proportion of 9E18tau in membrane fractions is substan-
tially reduced relative to nonmutant tau inwild-typemice, whereas
the proportion of 9A18tau associating with membranes is essen-
tially normal. These results conﬁrm that a proportion of tau is
membrane-associated in vivo and that this association is specif-
ically disrupted by phosphomimetic mutations. This is entirely
consistent with phosphorylation inhibiting the association of tau
with membranes in mice.
3.4. Reduced phosphorylation of 9E18tau, but not 9A18tau, in
mouse brain
We previously proposed a mechanistic link between reduced
microtubule association of P301L-equivalent mutant murine tau in
“P301L” tau knockin mice and its relative hypophosphorylation
(Gilley et al., 2012). We therefore assessed whether similar intrinsic
differences in phosphorylation of 9E18tau or 9A18tau occur in the
brains ofMapt-9E18 andMapt-9A18mice, and/or whether there are
staining process and/or differences in steady-state tau levels in the different genotypes). Boxed regions bordered by black dashed lines in each part are magniﬁed in image panels
immediately below. (A) Staining for tau is essentially undetectable in NF-L-positive mossy ﬁbers (MFs) in the CA3 and CA4 regions (middle panels) of 24-month-oldMapt-9E18 and
Mapt-9A18 mice. Pyramidal neurons in the same region also appear to showmore intense somatodendritic tau immunoreactivity in both knockins. Small boxed regions bordered by
solid black lines in the middle row of panels are magniﬁed top right of the same panel for clearer visualization of the soma of the pyramidal neurons. Small, intensely stained cells,
seen in all mice, are tau-positive oligodendrocytes (Migheli et al., 1988). (B) Somal tau immunoreactivity is increased in cells in the subgranular zone (SGZ) and neighboring cells in
the granule cell layer (GCL) of the DG in 3-week-oldMapt-9E18 mice and to a lesser extent inMapt-9A18 mice (arrows and magniﬁed panels, bottom row). Images are representative
of at least n ¼ 3 of each genotype at each age. There was no obvious deviation from the observations in the aged group over a range of ages spanning 21e28.5 months. Similar results
were obtained using two independent total tau antibodies (mTau2, shown, and B19).
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age-related changes in phosphorylation that could have additional
functional implications.
Soluble fractions of whole brain extracts from Mapt-9E18 and
Mapt-9A18 mice aged 8 or 24e26 months were probed with a va-
riety of phosphorylation-dependent tau antibodies raised against
human tau epitopes that are conserved in murine tau. The number
of epitopes we could examine was limited as many available anti-
bodies recognize sites that are already modiﬁed in the tau mutants.
Nevertheless, outside of the targeted region, we found that 9E18tau
was markedly hypophosphorylated at the murine equivalent of
human S396 at both ages, even accounting for reduced steady-state
levels of 9E18tau (Fig. 4A). In contrast, we saw no signiﬁcant dif-
ference in 9A18tau phosphorylation at this site at either age
(Fig. 4B). Similar results were obtained with the PHF-1 antibody,
which recognizes murine tau phosphorylated at residues equiva-
lent to human S396 and/or S404, but a general absence of reactivity
to a human S404 phosphorylation-dependent antibody suggests
phosphorylation is largely restricted to the S396-equivalent residue
in these mice (not shown). Therefore, as with “P301L” mutant
murine tau, reduced microtubule-binding capacity of 9E18tau cor-
relates with hypophosphorylation at this site.
Immunoreactive bands were also detected with
phosphorylation-dependent antibodies recognizing human tau
T181 (AT270) and S422, but phosphorylation of each mutant was
similar to wild-type tau at both ages (Fig. 4 and not shown). Finally,
none of the samples showed signiﬁcant reactivity to human S356
and S409 phosphorylation-dependent antibodies (not shown). This
implies these two sites are not normally phosphorylated in mice.
Although reduced phosphorylation has thus only been formally
shown at the murine equivalent of human S396, the more deﬁned
banding pattern consistently seen for 9E18tau on blots probed with
total tau antibodies could reﬂect hypophosphorylation at other,
untested sites. Crucially, no signiﬁcant age-related changes in
phosphorylation were observed for either of the tau mutants
(Fig. 4).
3.5. Absence of tau aggregation in Mapt-9E18 and Mapt-9A18
mouse brain
To investigate whether either knockin mouse line showed any
aggregation of insoluble tau during aging, we assessed tau levels in
insoluble fractions of whole brain extracts from wild-type and
knockin mice aged 8 or 24 months (counterparts to the soluble
fractions described in Section 3.3). These fractions were generated
using a method that maximizes the yield of insoluble, highly
phosphorylated tau (Hanger et al., 1998, 2007). We found that
insoluble 9E18tau was reduced relative to wild-type tau at both
ages (Fig. 5A), and insoluble 9A18tau was reduced at 8 months, but
not at 24 months (Fig. 5B). However, we found no signiﬁcant dif-
ference in the ratio of insoluble to soluble tau for either mutant at
either age (Fig. 5), suggesting the reductions in absolute levels just
reﬂect differences in steady-state levels of the mutants. Phos-
phorylation at residues equivalent to human tau T181, S356, S396,
S404, S409, and S422 was also either undetectable or equivalent to
that in soluble fractions (not shown), and no distinct hyper-
phosphorylated tau species with retarded electrophoretic mobility
were visible. Together, these data suggest that, up to 24 months of
age, neither mutant tau species forms pretangle aggregates in the
brains of Mapt-9E18 or Mapt-9A18 mice.
3.6. Altered subcellular distribution of 9E18tau and 9A18tau in the
absence of any tangle pathology or other toxic effects
Consistent with the absence of any increase in insoluble tau in
the brains of aged knockin mice, we did not detect any tau
aggregates and/or tangle pathology in either knockin line up to the
age of 24 months using Gallyas staining or immunohistochemical
staining with the phosphorylation-dependent PHF-1, AT270, or AT8
antibodies (not shown). In addition, whole-brain synaptophysin
levels are unaltered in both knockins at 24 months suggesting the
mutant proteins are not overtly toxic to synapses (Supplementary
Fig. 2A and B). However, staining for total tau revealed intriguing
age-related changes in the relative subcellular distribution of the
mutant proteins in both lines.
Clear qualitative changes in tau distribution were seen in both
the hippocampus and cerebellum. Changes in the hippocampus
are most evident in 24-month-old mice where tau staining of the
unmyelinated, small caliber granule cell axons of the mossy ﬁber
tract in the stratum lucidum of the CA3 and/or CA4 regions is
essentially absent in both mutants (NF-L staining conﬁrming
mossy ﬁbers are present) and where immunoreactivity of pyra-
midal neuron cell bodies in the adjacent and/or underlying stra-
tum pyramidale also appears increased (Fig. 6A and
Supplementary Fig. 4). The cross-sectional areas of different hip-
pocampal regions are unchanged in these aged mice suggesting
the altered distribution and/or altered properties of the mutants
do not impair neuron survival or induce signiﬁcant neuronal at-
rophy (Supplementary Fig. 3). In contrast, Mossy ﬁbers are tau
positive in young mice, and there is no clear increase in tau
staining in pyramidal neuron cell bodies. Instead, somatic staining
of cells in the subgranular zone and some adjacent granule cells
appears substantially increased in Mapt-9E18 mice, and to a lesser
extent in Mapt-9A18 mice (Fig. 6B). In the cerebellum, reduced tau
immunoreactivity is seen in the molecular layer of the cerebellar
cortex in 24-month-old Mapt-9E18 mice, with a moderate reduc-
tion also apparent in Mapt-9A18 mice (Fig. 7A and B). Signiﬁcant
alterations to the ratio of tau immunoreactivity between the mo-
lecular layer and granule cell layer (Fig. 7B) most likely reﬂect a
reduction in tau in the axons of granule cells (corresponding to the
abundant parallel ﬁbers in the molecular layer) relative to their
soma.
Unfortunately, the cellular complexity of brain tissue largely
precludes precise quantiﬁcation of tau redistribution between
different neuronal compartments due to frequent overlap of tau-
positive axons and soma and/or dendrites of different neuron
types in the same space. We therefore additionally assessed tau
distribution in dissociated cultures of early postnatal cortical
neurons and SCG neurons [a PNS neuron type that expresses a
broad range of low molecular weight tau isoforms at this stage
(Black et al., 1996)]. Whereas immunoﬂuorescent staining revealed
that distribution of the tau mutants appears relatively normal in
cortical neuron cultures from both knockin lines (Supplementary
Fig. 5), we found that 9E18tau distribution in Mapt-9E18 SCG
neuron cultures differs strikingly from that of tau in wild-type
cultures (Fig. 8A). Most notably, 9E18tau is relatively lacking in
their long, axon-like neurites. Distribution of 9A18tau in Mapt-
9A18 cultures, in contrast, appears relatively unaltered. 9E18tau
also appears relatively increased in Mapt-9E18 SCG cell bodies
using this method, but this is likely exaggerated by the low signal
in surrounding neurites. We therefore performed an immunoblot
analysis of ganglia (cell bodies and dendrites) and neurite (“axon”)
fractions from SCG explant cultures to accurately quantify the
changes. This conﬁrmed a relative paucity of 9E18tau in neurites
(Fig. 8B) but also indicated that in SCG neurons, there is no
reciprocal increase in 9E18tau in cell bodies and/or dendrites
(Fig. 8BeD). Thus, whole-cell 9E18tau is reduced in SCGs, relative
to wild-type tau in control cultures, consistent with reduced
expression of 9E18tau in whole brain (Figs. 3e5 and
Supplementary Fig. 2). Furthermore, and consistent with the
immunoﬂuorescence staining, immunoblotting conﬁrmed that
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distribution of 9A18tau in these developmentally young neurons is
essentially comparable to wild-type tau.
Together, these observations reveal consistent age-related
changes in subcellular localization of both mutant tau proteins in
some neuron types, with declines in axonal tau and accumulation of
tau in soma and/or dendrites both being seen (although not
necessarily simultaneously in the same neuron). However, there are
also a few situations where only mislocalization of 9E18tau is seen,
Fig. 7. Altered subcellular distribution of 9E18tau and 9A18tau in the cerebellum of knockin mice. (A) Representative immunohistochemical staining for total tau on brain tissue
sections encompassing the molecular layer (ML), Purkinje cell layer (PCL), and granule cell layer (GCL) of the cerebellum from wild-type, Mapt-9E18, and Mapt-9A18 mice aged
24 months. Lower panels are at higher magniﬁcation. Parallel ﬁbers (granule cell axons) in the molecular layer of the cerebellar cortex are strongly tau immunoreactive in wild-type
mice, but this reactivity is visibly reduced inMapt-9E18 mice, and to a lesser extent inMapt-9A18 mice. Staining of Purkinje cell bodies in the Purkinje cell layer of both mutants also
appears to be increased (arrows), but with some regional variation. Similar changes are seen in mice aged 21e26 months. Small, intensely stained cells present in sections of all ge-
notypes, and particularly evident in thewhitematter, are tau-positive oligodendrocytes (Migheli et al., 1988). (B) Graphs showing the relative optical density (OD) of tau staining in the
ML and GCL of the cerebellum, and the relative ML/GCL ratio, in Mapt-9E18 and Mapt-9A18 mice as a proportion of that in wild-type mice for mice aged 21e26 months (average
24months). Means SEM are plotted for data from n¼ 3e5 animals per genotype. **p< 0.01 and ***p< 0.001, one-way analysis of variance with Dunnett’s multiple comparisons post
hoc analysis. Abbreviation: SEM, standard error of the mean.
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or where 9E18tau mislocalization is clearly more pronounced.
Interestingly, these differences are most apparent in neurons at
earlier developmental stages.
3.7. Mitochondrial ﬂux is largely unaltered in Mapt-9E18 and
Mapt-9A18 tibial nerve axons
We previously identiﬁed changes in mitochondrial ﬂux in tibial
nerve axons of “P301L” tau knockin mice that we proposed may be
linked to reduced microtubule binding and/or altered phosphory-
lation of the mutant tau (Gilley et al., 2012). We therefore assessed
mitochondrial trafﬁcking in tibial nerve axons from wild-type and
Mapt-9E18 orMapt-9A18 mice that were additionally heterozygous
for the Thy1-mitoCFP-S (Mito-S) transgene (Misgeld et al., 2007). We
found slight reductions in anterograde and retrograde ﬂux of mito-
chondria in axons from bothmutants aged between 5 and 9months
(although these changes did not reach statistical signiﬁcance), and
average and maximum speeds of the motile mitochondria were
essentially unaltered (Supplementary Fig. 6). This contrasts with the
increased ﬂux of mitochondria observed in tibial nerve axons of
“P301L” tau knockin mice at a similar age (Gilley et al., 2012).
4. Discussion
Our characterization of knockin mice exclusively expressing
either phosphomimetic 9E18tau or phosphodefective 9A18tau
Fig. 8. Altered subcellular distribution of 9E18tau, but not 9A18tau, in primary Mapt-9E18 and Mapt-9A18 SCG neuronal cultures. (A) Representative images of immunoﬂuorescent
staining for total tau and bIII-tubulin (bIII-tub.) in dissociated SCG cultures fromwild-type,Mapt-9E18, andMapt-9A18 pups. Merge (þDAPI) images emphasize relative differences in
tau and bIII-tubulin staining and show the location of counterstained cell bodies. (B) Representative immunoblot showing relative levels of total tau and bIII-tubulin in neurites and
ganglia fractions from wild-type, Mapt-9E18, or Mapt-9A18 SCG explant cultures. Cultures are essentially devoid of non-neuronal cells, so separation of radial neurite outgrowth
from their ganglia generates a neurite fraction highly enriched for axon-like processes and a ganglia fraction containing predominantly cell bodies and short dendrites (Gilley and
Coleman, 2010; Peng et al., 1986). Slower migration of 9E18tau relative to wild-type tau is less evident in the SCG extracts compared to whole brains (see Fig. 1D and Fig. 4) likely due
to high levels of natural, developmental tau phosphorylation in these cultured neurons taken from early postnatal pups. (C) Graphs showing relative proportions of tau and bIII-
tubulin in neurite and ganglia fractions (neurite/ganglia ratios) and (D) graphs showing absolute total tau and bIII-tubulin levels in each fraction (a.u.¼arbitrary units). Means  SEM
are plotted for data from n ¼ 6 independent experiments. *p < 0.05 and **p < 0.01, repeated-measures one-way analysis of variance with Tukey’s multiple comparisons post hoc
analysis. Separate statistical tests were performed for ganglia and neurite fractions in (D). Abbreviation: SEM, standard error of the mean.
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(without overexpression) has revealed several changes to tau
function in vivo that are consistent with in vitro effects of altered
tau phosphorylation. These include substantial reductions in the
ability of 9E18tau to bind to and/or stabilize microtubules and to
associate with membranes, with only modest or no changes seen
for 9A18tau. Mislocalization of 9E18tau in some neuronal types also
appears outwardly consistent with phosphorylation-dependent
dissociation of tau from microtubules and relative redistribution
from axons into the somatodendritic compartment, both of which
have been proposed as critical early changes in the progression of
tau pathology (Bancher et al., 1989; Braak et al., 1994; Mietelska-
Porowska et al., 2014; Noble et al., 2013). However, we ﬁnd that
9A18tau is also mislocalized in some of the same neuron types,
especially in older mice, suggesting that 9E18tau mislocalization is
at least partly independent of the pseudophosphorylation. Never-
theless, whatever the underlying cause, mislocalization of exten-
sively pseudohyperphosphorylated 9E18tau does not appear to
induce argyrophilic (Gallyas positive) inclusions, or even pretangle
aggregation of tau, in mice up to at least 2 years of age. This result
therefore questions whether tau hyperphosphorylation alone
drives tau pathology, at least in mice.
The previous ﬁnding that pseudophosphorylation of just two of
the mutated residues in 9E18tau, S202 and T205, is sufﬁcient to
promote ﬁlament formation in vitro (Rankin et al., 2005), makes the
lack of advanced tau pathology in agedMapt-9E18 mice somewhat
surprising. One explanation may be that, because mice are rela-
tively short-lived, downstream pathological changes may not have
time to develop without localized or global overexpression of tau
itself and/or its modulators (Gilley et al., 2011, 2012). There is
also some debate about the relative propensities of murine and
human tau to aggregate and form ﬁlaments. Notably, endogenous
murine tau suppresses aggregation of wild-type or P301S mutant
human tau in two mouse models (Ando et al., 2010, 2011; Andorfer
et al., 2003), but there are also several situations where murine tau
displays clear pathogenicity. These include its capacity to form ﬁl-
aments as efﬁciently as human tau in vitro (Chohan et al., 2005;
Kampers et al., 1999), its ability to coaggregate with P301L
mutant human tau in 3Tg-AD transgenic mice and promote tangle
pathology (Baglietto-Vargas et al., 2014), and the fact that pre-
tangle and mature tau pathology can occur in the absence of
human tau in some mouse models (Adams et al., 2009; Cruz et al.,
2003; Liou et al., 2003). Because these models include p25 trans-
genic mice and Pin1/mice inwhich enhanced phosphorylation of
endogenous murine tau alone seems to drive pathology (Cruz et al.,
2003; Liou et al., 2003), it could be argued that the use of knockin
mice in this study should not, in itself, preclude the appearance of
tau pathology. Instead, a subset of mutations in 9E18tau could
counteract the otherwise pathogenic effects of extensive pseudo-
phosphorylation to account for the lack of late-stage tau pathology
in Mapt-9E18 mice.
Although hyperphosphorylation of tau might generally favor
aggregation (Iqbal et al., 2013), there is evidence that phosphory-
lation of some residues, including S214 and S262 (pseudophos-
phorylated in 9E18tau), can actually inhibit tau aggregation, even if
the sites are subsequently phosphorylated once paired helical ﬁl-
aments have formed (Schneider et al., 1999). Studies in a Drosophila
model also indicate there is some dissociation between tau phos-
phorylation and toxicity (Ambegaokar and Jackson, 2011;
Chatterjee et al., 2009). Furthermore, although glutamate sub-
stitutions in 9E18tau do mimic phosphorylation in several respects,
they may not fully replicate all aspects of this post-translational
modiﬁcation. Alternatively, these mutations could induce confor-
mational changes that inhibit oligomerization or truncation of tau,
both of which have been shown to promote assembly of tau into
ﬁlaments (Lasagna-Reeves et al., 2012; Zilka et al., 2012).
The differential effect of the phosphomimetic and phosphode-
fective mutations on the relationship between tau and microtu-
bules is also intriguing. A signiﬁcant reduction in recovery of
9E18tau in brain microtubule fractions clearly infers a substantial
effect of the glutamate substitutions on its capacity to bind mi-
crotubules, but, surprisingly, overall microtubule yield (based on
bIII-tubulin recovery) is comparable to wild-type controls. One
possible explanation is that the loss-of-function associated with
9E18tau might trigger compensatory changes during development
to restore normal microtubule dynamics, similar to those proposed
to occur in tau-deﬁcient mice (Harada et al., 1994). Determining the
nature of these changes could be revealing in terms of tau function
and, although it has been suggested that MAP1A upregulation may
compensate for a lack of tau during early development (Dawson
et al., 2001; Fujio et al., 2007; Harada et al., 1994), it seems likely
that there will be other critical changes that persist into adulthood.
In contrast, a signiﬁcantly reduced yield of microtubules from
Mapt-9A18 brains (despite only a modest reduction in 9A18tau
recovery, at best) would imply that the ability of 9A18tau to bind to
and/or stabilize microtubules is also compromised in someway, but
that this is not sufﬁcient to trigger compensatory changes.
The substantial reduction in 9E18tau association with microtu-
bules was perhaps predictable for two reasons. First, other pseu-
dohyperphosphorylated tau mutants show a similar defect in vitro
(Eidenmuller et al., 2001; Leger et al., 1997; Rodriguez-Martin et al.,
2013; Smith et al., 2000) and second, the PRD, which normally in-
teracts with the repeat domains to enhance this association (Brandt
and Lee, 1993; Goode et al., 1997; Trinczek et al., 1995), is heavily
modiﬁed in 9E18tau. However, the effects of combinatorial tau
pseudophosphorylation at multiple sites are not easy to predict
(Kiris et al., 2011), and it is notable that the extensively pseudo-
phosphorylated human PHP tau does not appear to be defective for
microtubule binding in cortical extracts (Hundelt et al., 2011). Only
5 of the 10 phosphomimetic mutations in human PHP tau match
those in 9E18tau (S198E, S199E, S202E, T231E, and S235E), so
reduced association of 9E18tau with microtubules can likely be
attributed to one or more of its other 13 modiﬁcations. Signiﬁcantly
perhaps, this includes S262E in the ﬁrst microtubule-binding repeat
which alone has been shown to have a profound effect on the ability
of tau to bind to and stabilize microtubules in vitro (Biernat et al.,
1993; Drewes et al., 1995; Smith et al., 2000). In contrast, any po-
tential reduction in the ability of 9A18tau to bind to and/or promote
assembly of microtubules is at odds with enhanced microtubule
association reported for the related, but distinct, phosphodefective
human tau mutant, A18tau (Rodriguez-Martin et al., 2013).
Although 9A18tau and human A18tau share 11 of 18 mutations, it is
notable that two of the mutations unique to 9A18tau, S258A, and
S262A are located within the ﬁrst microtubule-binding repeat of
tau. If either directly inﬂuencesmicrotubule interactions in any way
(unrelated to their inability to be phosphorylated), then it could
account for any differences between the two phosphodefective
mutants.
The correlation between the substantially reduced microtubule-
binding capacity of 9E18tau and greatly reduced phosphorylation at
the equivalent of human S396 in mouse tau is revealing because it
supports our previous hypothesis, based on a similar correlation
seen for “P301L” mutant tau, that defective microtubule binding
reduces the need for nonpathological tau phosphorylation as a
means to regulate microtubule dynamics (Gilley et al., 2012).
Importantly, although the origin of the microtubule-binding defect
is different for 9E18tau and “P301L” tau (pseudohyperphosphor-
ylation vs. a disease-associated mutation), the outcomedreduced
natural phosphorylation at S396dis the same. However, the sig-
niﬁcance of phosphorylation at this particular site is not clear; S396
pseudophosphorylation in human PHP tau does not alter
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microtubule-binding in vivo (Hundelt et al., 2011), and it has only
relatively modest effects on tau microtubule binding and/or
microtubule assembly function in vitro (Ding et al., 2006; Smith
et al., 2000). Therefore, rather than having a direct effect on tau
binding to microtubules, S396 phosphorylation may instead be
involved in the ﬁne tuning of this interaction.
Given that membrane-associated tau has previously been
shown to be largely dephosphorylated (Pooler et al., 2012), reduced
membrane association of 9E18tau in Mapt-9E18 brain is also likely
to be primarily a direct effect of its extensive pseudophosphor-
ylation. This is further supported by the unaltered membrane as-
sociation of 9A18tau in Mapt-9A18 brain. However, the large
number of glutamate substitutions in 9E18tau, together with their
limited overlap with other phosphomimetic mutants that show
reduced membrane association (Eidenmuller et al., 2001; Pooler
et al., 2012), precludes identiﬁcation of speciﬁc sites that regulate
this interaction. Modiﬁcation of sites within or ﬂanking PXXP mo-
tifs at residues 213-216 and/or 233-236 in the PRD domain of
9E18tau (human 2N4R tau numbering), including, but not restricted
to T212E, S214E, T217E, T231E, S235E, and S237E, likely make some
contribution as these motifs mediate phosphorylation-sensitive
interaction of tau with membrane-associated SH3 domain-
containing proteins, such as the protein tyrosine kinase FYN
(Arrasate et al., 2000; Lee et al., 1998; Pooler et al., 2012; Reynolds
et al., 2008). Overall (pseudo)phosphorylation load may also be
important, given that pseudophosphorylation of other sites in the
N-terminal half of tau can also independently inhibit tau associa-
tion with membranes (Pooler et al., 2012). Of course, a contribution
of pseudophosphorylation-independent effects, such as altered
conformation induced speciﬁcally by the glutamate substitutions in
9E18tau, also cannot be ruled out.
The signiﬁcant similarity in the mislocalization of 9E18tau and
9A18tau in neurons indicates that changes unrelated to their
(pseudo)phosphorylation status are likely to be determinants of the
phenotype, although pseudophosphorylation may still contribute
to the seemingly more widespread and/or earlier mislocalization of
9E18tau. Several mechanisms have been proposed for subcellular
sorting of tau (Zempel and Mandelkow, 2014), and common
structural changes induced by both sets of mutations, perhaps
speciﬁcally in relation to the conformation of the PRD, might
interfere with any number of them. Disruption of two of the best
characterized, a retrograde barrier in the axon initial segment that
prevents tau re-entry into the soma (Li et al., 2011) and the pref-
erential stabilization of tau in axons (Hirokawa et al., 1996), would
be predicted to promote loss of tau from axons and/or its somato-
dendritic accumulation, similar to the mislocalization seen in both
knockins. Both are also inﬂuenced bymicrotubule-binding capacity,
thus providing another possible explanation for differences be-
tween the two mutants. An anterograde sorting mechanism could
be an attractive alternative mechanism, but common suppression
of anterograde trafﬁcking of 9E18tau and 9A18tau seems unlikely
given that the anterograde ﬂow of other, partially related, phos-
phomimetic and phosphodefective tau mutants is differentially
affected in primary rat cortical neurons (Cuchillo-Ibanez et al.,
2008).
Whatever the mechanisms responsible for 9E18tau and 9A18tau
mislocalization, variation in their efﬁcacy in different neuron types
or at different developmental stages could explain the apparent
regional and temporal differences in mislocalization of the tau
mutants. However, it is notable that reduced axonal levels of the
mutants are most evident in vivo in neurons with unmyelinated,
small caliber axons. Although it is possible that these neurons are
the most susceptible to changes in tau homeostasis (Harada et al.,
1994), the fact that their axons are also the most strongly tau
immunoreactive raises the possibility that the phenotype is actually
more widespread but simply cannot be visualized in other neuron
types using standard immunohistochemistry techniques. Addi-
tional considerations include the possibility that reduced steady-
state levels of 9E18tau, evident both in whole brain and SCG
neuron cultures, make axonal deﬁciency of 9E18tau more percep-
tible than 9A18tau in some cases, or that some of the examples of
mislocalization might instead reﬂect a developmental defect (e.g.,
in the subgranular zone of the dentate gyrus).
At present, the underlying basis for the counterintuitive differ-
ences in the steady-state levels of the mutant proteins and their
mRNAs is not known. A possible reduction in 9E18tau stability in
axons could perhaps account for the disparity between reduced
steady-state levels of the protein and normal levels its mRNA in
brain. However, in some contexts, phosphorylation has actually
been shown to delay the proteasome-mediated turnover of tau via a
mechanism that may involve Hsp90 (Dickey et al., 2007; Luo et al.,
2007; Poppek et al., 2006; Rodriguez-Martin et al., 2013). Instead,
reduced 9E18tau levels might reﬂect suboptimal translation, with
the highly localized clustering of the substituting glutamate codons
in Mapt-9E18 mRNA perhaps interfering with translational proc-
essivity. In contrast, changes at both the mRNA and protein levels
are required to explain normal levels of 9A18tau protein in Mapt-
9A18 brain when there is a simultaneous relative paucity of Mapt-
9A18 mRNA. We speculate that transcription from the Mapt9A18
knockin alleles could be impaired by exceptionally high GC-content
in the targeted region (77% over 200 base pairs), although this
would additionally require that 9A18tau is either more stable than
wild-type tau, or is translated more efﬁciently, to account for
normal expression of protein from a less-abundant mRNA pool.
Finally, we had also previously proposed a link between reduced
microtubule-binding capacity and/or hypophosphorylation of
“P301L” murine tau and the increased anterograde ﬂux of mito-
chondria in tibial nerve axons in relatively young “P301L” murine
tau knockin mice (Gilley et al., 2012). The absence of similar effects
on mitochondrial trafﬁcking in Mapt-9E18 tibial nerve axons,
despite 9E18tau showing seemingly more pronounced changes to
these properties, seems to rule out their involvement in increasing
anterograde transport. However, compensatory changes (as dis-
cussed previously) could mask similar effects if they are triggered
during development in response to the severe dysfunction associ-
ated with 9E18tau, but not the more moderate dysfunction of
“P301L” murine tau (Gilley et al., 2012). Notably, both the yield and
tau/tubulin ratio of microtubules appear to be reduced in knockin
mice exclusively expressing “P301L” tau (Gilley et al., 2012). This
differentiates these mice from both Mapt-9E18 and Mapt-9A18
mice where just one or other, but not both, are altered and could
explain why only “P301L” murine tau knockin mice display alter-
ations in mitochondrial trafﬁcking.
To conclude, our characterization of complementary Mapt-9E18
and Mapt-9A18 phosphomimetic and phosphodefective tau
knockin mice provides important new insight into the potential
impact of phosphorylation of the PRD and neighboring ﬁrst MTBD
on a number of key properties of tau when expressed at near-
physiological levels in vivo. Crucially, the ﬁndings also raise a
number of important questions about the role of tau hyper-
phosphorylation in the pathogenesis of human tauopathies. These
questions can be addressed in future studies of other phosphomi-
metic and phosphodefective tau animal models.
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